Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results

SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three and six months ended June 30, 2008.

"As we've previously stated, we continue to increase our focus and resources on our proprietary programs that target large markets. Now we are beginning to see tangible results of that effort. Data from recent presentations at medical conferences validates the strength of our technology platform across multiple therapeutic areas," said Jonathan Lim, MD, President and CEO of Halozyme. "For example, Phase I clinical results showed faster absorption and onset for insulin when co-administered with our PH20 enzyme, a profile more similar to the body's own natural insulin. This could lead to the development of a best-in-class product. We have also demonstrated in animal models significant tumor suppression for PEGPH20 plus chemotherapy and controlled degradation of a structural component of the skin with HTI-501 that may prove beneficial in various dermatologic conditions. Over the next six months, we plan to initiate additional clinical trials to enhance the value of our pipeline."

Recent Scientific Achievements

-- Presentation of Phase I clinical results from the Company's diabetes

mellitus program at the American Diabetes Association's 68th Scientific

Sessions. The data showed that combining the Company's proprietary

recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R)

(regular insulin human) or Humalog(R) (insulin lispro) yielded

pharmacokinetics and glucodynamics that better mimicked physiologic

prandial (mealtime) insulin release and activity than Humulin R or

Humalog alone. Statistically significant pharmacokinetic (PK) and

glucodynamic (GD) improvements observed in the study include:

Significantly faster systemic absorption of each insulin starting with

the first observation time point of three minutes after injection,

faster and greater glucose lowering activity early after injection,

greater peak insulin levels for the same dose administered, lower

variability of key PK and GD variables across subjects, and improvement

for rHuPH20 in combination with Humulin across all parameters when

compared to Humalog alone.

-- Release of Chemophase(R) Phase I/IIa clinical results from a continuing

clinical trial in the treatment of superficial bladder cancer. Based

on the results, the Chemophase combination treatment of mitomycin plus

the rHuPH20 enzyme was well tolerated and appears safe. The study

reported no dose-limiting toxicities and no observed side effects

attributable to the enzyme, and established the dose for subsequent

clinical trials, therefore achieving the pre-defined primary objective

of the study. In addition, there were no neutralizing antibodies to

rHuPH20 detected and the plasma concentration of mitomycin was either

non-measureable or negligible and well below the threshold that may be

predictive for myelosuppression (a decrease in bone marrow activity,

resulting in fewer red blood cells, white blood cells, and platelets).

-- New findings of positive pre-clinical animal efficacy data for

pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for

Cancer Research (AACR) Translational Cancer Medicine meeting in

Monterey, CA. The study showed that treatment of hormone resistant

human prostate cancer in tumor bearing mouse models with intravenous

PEGPH20 in combination with the chemotherapeutic drugs, docetaxel

(Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a

substantial increase in anti-tumor activity. The docetaxel combination

treatment demonstrated significantly enhanced survival compared to

treatment with the chemotherapeutic agent alone. The effects of PEGPH20

were selective to prostate tumors producing hyaluronan, consistent with

the selective reduction of tumor interstitial fluid pressure. Treatment

with PEGPH20 was well tolerated without significant increases in

neutropenia (depletion of neutrophils, a type of white blood cell)

compared to chemotherapy alone.

-- New pre-clinical findings on the controlled modification of the

extracellular matrix with HTI-501 at the European Society for

Dermatological Research and Japanese Society for Investigative

Dermatology. HTI-501, a new recombinant human lysosomal proteinase

that could provide an effective dermatologic treatment by targeting and

degrading the fibrous components of the extracellular matrix in a

highly controlled fashion. This new molecular entity is being explored

as a potential solution for medical, as well as aesthetic, dermatology

indications for which surgery may be impractical, such as cellulite and

certain forms of scarring. HTI-501 works by a process called enzymatic

subscision, which involves degradation of fibrous septae (or cords) in

a controllable and predictable manner to release skin tissue from the

fibrous cords and smooth out the surface contour. It could be

especially beneficial in aesthetic dermatology indications.

Second Quarter 2008 Financial Results

-- Net loss for the second quarter of 2008 was $11.0 million, or $0.14 per

share, compared with a net loss for the second quarter of 2007 of $4.8

million, or $0.07 per share. Net loss for the six months ended June

30, 2008 was $21.0 million, or $0.27 per share, compared with a net

loss of $8.2 million, or $0.11 per share, for the comparable period

last year.

-- Revenues for the second quarter of 2008 were $1.4 million, compared

with $709,000 for the second quarter of 2007. Revenues under

collaborative agreements for the second quarter of 2008 were $1.4

million, compared with $539,000 for the second quarter of 2007.

Revenues under collaborative agreements in 2008 primarily consisted of

the amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter of

$554,000 and Roche of $210,000. Cumulase(R) product sales for the

second quarter of 2008 were $48,000, compared with $139,000 for the

second quarter of 2007.

-- Research and development expenses for the second quarter of 2008 were

$8.9 million, compared with $4.1 million for the second quarter of

2007, reflecting increased compensation expenses including share-based

compensation expenses, research and development spending on the

Company's Insulin, Bisphosphonates, and PEG PH20 clinical and

pre-clinical programs, and production costs associated with the

manufacturing scale-up of the Company's rHuPH20 enzyme.

-- Selling, general and administrative expenses for the second quarter of

2008 were $3.8 million, compared with $2.4 million for the second

quarter of 2007, reflecting increases in compensation expenses

including share-based compensation expenses, as well as higher legal

and facilities expenses compared with the prior-year quarter.

-- Cash and cash equivalents were $82.4 million as of June 30, 2008,

compared with $97.7 million as of December 31, 2007.

Conference Call

Halozyme management will host a pipeline update conference call today to discuss these topics beginning at 8:00 a.m. PT (11:00 a.m. ET). To participate via telephone, please call 888-256-9044 for domestic callers, or 706-643-5585 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reservation number is 44830661. The conference call will be broadcast live over the Internet at and the replay will be available on the Company's website for 30 days.


HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in the formulation. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX recombinant if sensitization occurs. Hyaluronidase should not be applied directly to the cornea, and should not be injected around infected or acutely inflamed areas, nor used to reduce the swelling of bites or stings. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated. Furosemide, the benzodiazepines, and phenytoin are incompatible with hyaluronidase. Please see accompanying package insert at for full Prescribing Information.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements relating to an insulin product and conclusions and implications drawn from clinical and pre-clinical trial data) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contact

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215




Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007


Revenue under


agreements $1,351,492 $539,434 $3,015,572 $1,162,563

Product sales 82,727 169,082 224,165 356,168

Total Revenues 1,434,219 708,516 3,239,737 1,518,731


Cost of product

sales 37,126 75,518 74,316 151,746

Research and

development 8,925,488 4,083,885 17,369,679 6,913,249


general and

administrative 3,846,175 2,381,827 8,003,778 4,366,861

Total Operating

Expenses 12,808,789 6,541,230 25,447,773 11,431,856


OPERATIONS (11,374,570) (5,832,714) (22,208,036) (9,913,125)

Interest income 372,180 1,031,007 1,251,649 1,754,114

NET LOSS $(11,002,390) $(4,801,707) $(20,956,387) $(8,159,011)

Basic and diluted

net loss per share $(0.14) $(0.07) $(0.27) $(0.11)

Shares used in

computing net

loss per share,

basic and

diluted 79,454,496 73,217,967 78,923,520 71,610,380



AS OF JUNE 30, 2008 AND DECEMBER 31, 2007

June 30, December 31,

2008 2007



Cash and cash equivalents $82,410,139 $97,679,085

Accounts receivable 1,160,990 779,825

Inventory 649,254 703,468

Prepaid expenses and other assets 1,895,820 2,014,680

Total current assets 86,116,203 101,177,058

Property and equipment, net 2,439,765 2,283,316

Total Assets $88,555,968 $103,460,374


Accounts payable $2,814,512 $3,055,637

Accrued expenses 3,338,896 2,502,259

Deferred revenue 3,255,461 3,306,225

Total current liabilities 9,408,869 8,864,121

Deferred revenue, net of current portion 38,376,170 35,963,266

Deferred rent, net of current portion 1,116,892 865,063

Stockholders' Equity:

Common stock 80,099 77,904

Additional paid-in capital 125,525,748 122,685,443

Accumulated deficit (85,951,810) (64,995,423)

Total stockholders' equity 39,654,037 57,767,924

Total Liabilities and

Stockholders' Equity $88,555,968 $103,460,374

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):